Recent developments of protein kinase inhibitors as potential AD therapeutics

Volkmar Tell and Andreas Hilgeroth*

Research Group of Drug Development and Analysis, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle, Germany

*Correspondence: andreas.hilgeroth@pharmazie.uni-halle.de

Present Alzheimer’s disease (AD) therapies suffer from inefficient effects on AD symptoms like memory or cognition, especially in later states of the disease. Used acetylcholine esterase inhibitors or the NMDA receptor antagonist memantine address one target structure which is involved in a complex, multifactorial disease progression. So the benefit for patients is presently poor. A more close insight in the AD progression identified more suggested target structures for drug development. Strategies of AD drug development concentrate on novel target structures combined with the established ones dedicated for combined therapy regimes, preferably by the use of one drug which may address two target structures. Protein kinases have been identified as promising target structures because they are involved in AD progression pathways like pathophysiological tau protein phosphorylations and amyloid β toxicity. The review article will shortly view early inhibitors of single protein kinases like glycogen synthase kinase (gsk3β) and cyclin dependent kinase 5. Novel inhibitors will be discussed which address novel AD relevant protein kinases like dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A). Moreover, multitargeting inhibitors will be presented which target several protein kinases and those which are suspected in influencing other AD relevant processes. Such a multitargeting is the most promising strategy to effectively hamper the multifactorial disease progression and thus gives perspective hopes for a future better patient benefit.

Keywords: protein kinase, inhibitor, tau phosphorylation, small molecules, structure-activity relationships, inhibitor binding

INTRODUCTION

Presently Alzheimer’s disease (AD) therapies are limited by the availability of just two groups of drugs with one group consisting of just one drug. Acetylcholine esterase inhibitors increase the neuronal acetylcholine amounts, whereas memantine, an antagonist at the neuronal N-methyl d-aspartate (NMDA) receptor, reduces a neuronal overstimulation caused by the neurotransmitter glutaminic acid (Birks, 2006; McShane et al., 2006). Both the loss of acetylcholine and the neuronal overstimulation contribute to the decay of neurons and thus the AD progression. However, the patient benefit of the present drugs is poor and limited to the early stage of the disease (erry and Buccafusco, 2003; Raina et al., 2008). Memory, cognition, and daily behavior for life managing is hardly improved by the drugs in later stages of a severe AD (erry and Buccafusco, 2003; Raina et al., 2008). It is known that AD is a multifactorial disease which means that different pathophysiological factors all contribute to the AD progression (lphal and Grundke-Iqbal, 2008; Marco et al., 2010). Protein kinases are known to mainly contribute to these toxic events as they play a central role in the cellular pathways of regulated cell function and division.

With the understanding of various protein kinase functions the question of developing inhibitors as potential AD therapeutics has arisen. Protein kinase inhibitors are long established in cancer therapies where they regulate the overactivity of protein kinases which lead to uncontrolled cell divisions, cell migration, and cellular invasion (Krug and Hilgeroth, 2008; Zhang et al., 2009). The toxicity of such anticancer protein kinase inhibitors has always been a critical question of causing toxic or undesired side-effects (Liao and Andrews, 2007). Viewing the years of research in this field multitargeting protein kinase inhibitors established and are well tolerated by patients with only limited side-effects (Krug and Hilgeroth, 2008). So there are certain perspectives that protein kinase inhibitors for AD therapy may show promising effects in the pathophysiological AD process on one hand and for a more effective therapy on the other hand with respect to the knowledge that present drugs are no real perspective drugs to effectively influence...
the disease progression. The review will give a short summary of the early protein kinase inhibitors which target early known single target structures. Such early protein kinase inhibitors have been developed to reduce the activity of tau protein hyperphosphorylating kinases which have been found partly overactive or overexpressed in respective neuronal cells in AD brains and thus mainly contribute to the aggregation and loss of function of the hyperphosphorylated tau. Then novel inhibitors will be viewed which address novel targets with evidence for the AD progression and those which are dedicated to a multitargeting of more than one target structure.

EARLY PROTEIN KINASE INHIBITORS

Tau protein has been the main target structure for protein kinase inhibitors since tau protein was found hyperphosphorylated in AD brains. The tau protein hyperphosphorylation results in dissociation from the microtubules the function of which is supported by tau protein (Martin et al., 2013). Moreover, the hyperphosphorylation causes a loss of solubility and leads to the formation of paired helical filaments (PHFs) which further aggregate to NFTs (Avila, 2006; Martin et al., 2011, 2013). The reason for the tau protein hyperphosphorylation is an imbalance of phosphorylation and dephosphorylation of tau. This imbalance is partly driven by a reduced tau protein dephosphorylation or by an overactivity of the phosphorylating protein kinases (Iqbal and Grundke-Iqbal, 2002; Tian and Wang, 2002; Pei et al., 2008; Martin et al., 2013). Glycogen synthase kinase (GSK) 3β plays a central role in the tau phosphorylation process. It has been reported that 31% of the pathological phosphorylation sites of tau protein are phosphorylated by GSK3β (Martin et al., 2013). GSK3β has been found co-localized with NFTs and is found overexpressed in AD brains with increased activity (Pei et al., 1997; Leroy et al., 2007). Toxic Aβ is known to increase the activity of GSK3β which contributes to an increased Aβ production via the tau phosphorylation (Hosoi et al., 1996; Takashima et al., 1996). Therefore GSK3β forms a link of Aβ toxicity and tau pathology (Martin et al., 2013). Lithium as an early GSK3β inhibitor reduced tau phosphorylation and prevented reversed aspects of tau pathology in animal models (Tarlov and Aisen, 2009). However, treatment of AD patients with mild AD in the early disease stages showed no improvement in cognition (Hampel et al., 2009). The result correlated with unchanged AD biomarkers in the cerebrospinal fluid (CSF) of the patients, namely phosphorylated tau, total tau, and toxic Aβ (Hampel et al., 2009). Several GSK3β inhibitors are under development belonging to the paullone, indirubin, and the maleimide families. However, no representative of these inhibitor groups reached clinical trials (Aisen et al., 2009). Therefore GSK3β inhibitors are under development belonging to the paullone, indirubin, and the maleimide families. However, no representative of these inhibitor groups reached clinical trials so far. Reasons for their failure have been proven cytotoxic effects.

The other important tau protein kinase which is involved in pathophysiological tau protein phosphorylation is the cyclin dependent kinase 5 (cdk5). The normally cdk5 regulating protein p35 is found truncated in AD brains to 23 amino acids. This protein p25 leads to a constitutive activation of cdk5 and thus causes the pathophysiological tau phosphorylation (Patrick et al., 1999). The hyperphosphorylated tau protein dissociates from the microtubules and forms NFTs on cdk5 induction by p25 (Cruz et al., 2003; Noble et al., 2003). Also NFTs are phosphorylated by cdk5 action (Baumann et al., 1993; Hollander et al., 1996). Cdk5 phosphorylated tau becomes a better substrate for GSK3β so that excessive tau phosphorylation proceeds (Sengupta et al., 1998). Moreover, cdk5 promotes apoptosis in AD brains which may follow Aβ toxicity influenced by the hyperphosphorylated tau or by remaining p35 protein (Hamdanee et al., 2005; Utreras et al., 2009).

From the number of cdk inhibitors which were all non-selective like flavopiridol a pan-cdk inhibitor investigated for cancer therapy, cdk5-selective so-called CP-inhibitors were reported with nanomolar affinities and the ability to cross the blood brain barrier (Wen et al., 2008). They were described to reduce increased Aβ levels on p25 overexpression. However, as far as known these inhibitors remained in preclinical states.

NOVEL INHIBITORS

SINGLE PROTEIN KINASE TARGETING OF CDK5, P38, JNK, ERK, CK, AND DYRK1A

Due to the significant role of cdk5 in tau phosphorylation there have been ongoing efforts to develop novel inhibitors of the kinase which have been structurally based on the cdk inhibitor roscovitine (seliciclib) as a trisubstituted purine compound (Figure 1).

Beside cdk5 roscovitine inhibits several cdk's like cdk1, cdk2, or cdk9 in micromolar concentrations (Bettayeb et al., 2008). It presently undergoes clinical trials of various types of cancer (U.S. National Institutes of Health, 2010). However, roscovitine crosses the blood brain barrier and this advantage might have been further studied because only about 2% of small molecule inhibitors are able to penetrate into the CNS (Meijer and Raymond, 2003; Pasdrière, 2005). One structurally varied compound has been DRF 53 with a 2-pyridyl residue attached to the 4-position of the benzylamine substituent. With a similar cdk inhibition profile the toxic properties increased compared to roscovitine so that it is suggested to be used as anticancer agent like roscovitine (Bettayeb et al., 2008). In a recent paper the 2-pyridyl residue has been changed by both a 3- and a 4-pyridyl residue (Demange et al., 2013). More favourable cdk5 inhibition data resulted in nanomolar ranges. Docking studies in the ATP binding pocket demonstrated a hydrogen bonding of the 4-pyridyl nitrogen to the Nc of Lys89 of the protein backbone to explain the increased activity. However, beside cdk5 also cdk2 was inhibited and all derivatives were toxic (Demange et al., 2013).

P38 protein kinase belonging to the mitogen activated protein kinases (MAPKs) is a tau protein phosphorylating kinase which contributes to tau protein dissociation from the microtubules and facilitates a further tau aggregation (Martin et al., 2013). In AD brains Aβ activates p38 isoforms p38α and p38β via activated gila (Riou et al., 2008). In the following proinflammatory cytokines are produced like interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) (Shaftel et al., 2008). So nanomolar active p38 inhibitor SB-239063 is able to reduce the inflammatory cytokine production (Underwood et al., 2008).

Erk isoforms 1 and 2 contribute to abnormal tau protein phosphorylation including the formation of pathologival tau conformations (Pei et al., 2012; Martin et al., 2013). So the inhibition of Erk promises a reduced tau pathology. FR-180204 is the sole selective Erk inhibitor described so far (Ohsori et al., 2005).
Finally, JNKs of the MAPK family have been interesting target structures because they also contribute to tau phosphorylation. JNK activation is mediated by toxic Aβ fragments (Philpott and Facci, 2008). However, activated JNKs also increase the γ-secretase activity and thus contribute to increased toxic Aβ levels resulting from the amyloid precursor protein (APP) by γ-secretase cleavage (Shen et al., 2008). Both MAPKs p38 and JNK have been co-purified with NFTs in AD brains (Zhu et al., 2000). So JNKs are potential AD-therapeutic target structures. SP-600125 is a potent JNK isoform inhibitor (Bennett et al., 2001). However, JNK3 is the known isoform which mediates the toxic response to Aβ with a greater role in the regulation of toxicity in brain than the other isoforms JNK1/2 (Philpott and Facci, 2008). So it would be of benefit to develop a more exclusive JNK3 inhibitor.

Casein kinase isoforms CK1δ and CK1ε are expressed in brain and are mainly involved in the pathophysiological tau phosphorylation with 26% of those tau amino acids being phosphorylated by CK1 (Knippschild et al., 2005; Martin et al., 2013). CK1δ mRNA
levels as well as the kinase itself are found mainly increased in AD brains up to 30-fold (Yasojima et al., 2000). CK1α has been found to co-localized with NFTs like GSK3β being active in the tau phosphorylation of NFIs (Kuret et al., 1997; Schwab et al., 2000). Moreover, CK phosphorylation of tau sites facilitates the dissociation from the microtubules (Martin et al., 2013). Similar to GSK3β, CK1α peptides activate CK1α thus triggering the tau pathology which on the other hand increases Aβ (Takahama et al., 1996; Fajardo et al., 2007). Furthermore, CK1ε is known to play a role in the APP processing, likely by regulating the activity of γ-secretase which contributes to the formation of the toxic Aβ peptides. CK1α is also a promising kinase for GSK3β and has a regulatory role in cdk5 function (Knipschild et al., 2005).

Thus, CK1α is an interesting target structure for AD relevant protein kinase inhibitors, because the AD overactivity of the kinase may be regulated by an inhibitor without affecting the basic activity in cells. The presently known CK1α inhibitors IC-261 and tetrabromocinnamic acid (TBCA) are poor inhibitors with activities in partly higher micromolar ranges (Mashhoon et al., 2000; Pagano et al., 2007).

Dual-specificity tyrosine phosphorylation-regulating kinase 1A (DYRK1A) phosphorylates tau and transcription factor cAMP Response Element Binding (CREB) which is involved in learning and memory (Yang et al., 2001). Aβ peptides increase DYRK1A mRNA levels in AD brains (Kimura et al., 2007). However, tau phosphorylation of DYRK1A is reported to be triggered by GSK3β (Kimura et al., 2007). Interestingly, DYRK1A phosphorylates serine 202 of tau protein and this phosphorylation induces a conformational change of tau which is pathological (Martin et al., 2013). Thus, DYRK1A emerged to an interesting protein kinase for a tau-directed therapy. Harmane is an early DYRK1A inhibitor which inhibits not only the enzyme itself but also its tyrosine autophosphorylation (Seifert et al., 2008). While harmine is a non-competitive inhibitor which was reported to reduce the production of proinflammatory cytokines (Kim et al., 2004), MW01-2-069A was demonstrated to attenuate Aβ-mediated decreases of synaptophysin as a presynaptic protein. The downregulation of synaptophysin causes synaptic dysfunctions in the hippocampus and following hippocampal behavioral deficits. Favorably, the compound passes the blood brain barrier and proved to be metabolically stable to an extent of 70% (Munoz et al., 2007). However, the inhibitory activity in submicromolar ranges has to be considered critically with respect to later clinical studies.

The protein kinase Rock has been demonstrated to be activated in neurites surrounded by amyloid deposits (Petratos et al., 2008). The following outgrowth of the neurites could be protected by Rock inhibitor V-27632. Moreover, an amyloid-induced loss of synapses could be retracted, so that novel synapse formation were observed. Furthermore the Rock inhibitor interfered with the APP processing by an increase of the γ-secretase activity leading to less toxic Aβ (Quin et al., 2006).

τ-oxoaloxafluorenes discovered as moderate cdk1 inhibitors first have been further developed as selective GSK3β inhibitors with a 3-carboxyl amide function at the 3-position of the molecular scaffold (Voigt et al., 2008) and a loss of the cdk1 inhibition. While the pyridine nitrogen atom of the 3-carboxyl derivatives showed optimized hydrogen bonding to the NH function of amino acid Val135 of the protein backbone, the NH amide function bound to carbonyl amide function of Thr138 via a water
Tell and Hilgeroth AD-relevant protein kinase inhibitors

**FIGURE 2 | Multitargeting inhibitors.**

molecule. Further variations at the molecular scaffold led to the benzo-annelated lead compounds which further profiled as cdk1, gsk3β and cdk5 inhibitors (Tell et al., 2012a). The binding mode of those benzo-annelated naphtho compounds to the protein kinase backbone was demonstrated to be inverse compared to the early 1-aza-9-oxafluorenes with an orientation of the 3-substituent within the hydrophobic binding pocket nearby the gatekeeper amino acids (Voigt et al., 2008; Tell et al., 2012a). One nanomolar active 3-hydroxy compound showed exclusive cdk1, gsk3β and cdk5 inhibition properties and proved to be non-toxic in various cellular assays (Tell et al., 2012b). It effectively inhibited tau phosphorylation of various tau amino acids and has been suggested for further tau pathology studies in tau mice models.

**CHALLENGES**

During the last decades of AD research it has become more obvious that AD is not only a multifactorial disease with various pathological events which contribute to the disease progression but also a cross-linked disease. Aβ toxicity has been demonstrated to increase tau pathology. The linker has been GSK3β which itself is known to increase the production of Aβ. GSK3β has been known to be primed by cdk5 so that the inhibition of cdk5 reduces Aβ toxicity. Synaptic dysfunctions are not only mediated by a decrease of acetylcholine, but also by Aβ-induced increases of presynaptic proteins. Moreover, Aβ mediates inflammatory brain processes via protein kinases.
The low benefit of drugs which target one single target structure enforced studies for a potential multitargeting. The early strategy in this field concentrated on the combination of differently acting drugs by linker like alkyl chains. The outcome of these studies is poor. However, combining of two drugs by a linker leads to new molecules with changed molecular properties. Resulting enlarged binding influence results for instance in brain entry properties. It will be a challenge to develop a favourable combined drug for AD therapy.

Protein kinases have been identified as mainly disease influencing target structures. Their central role in tau pathology by tau phosphorylation is extended to disease-linking processes and makes them to most interesting target structures.

Limits in the development of AD-relevant protein kinase inhibitors have been pointed out: the brain entry of such small molecules, toxic cell effects which accompany also recent inhibitors and highly active molecules. The latter aspect became obvious by recent studies with GSK3β inhibitors. None of the highly active inhibitors reached clinical trials. A micromolar inhibitor seems to be more promising. What can be the conclusion from all these points? It will be of great interest to develop a drug which itself has such multitargeting properties. As protein kinases are promising target structures further developments shall concentrate on a multitargeting protein kinase inhibitor which has to be profiled in the various ways like brain entry abilities, low cellular toxicity and finally a sufficient but not too strong activity just to regulate the protein kinases’ overactivities and not to interfere with their activities in normal cells. 1-Aza-9-oxafluorenes from a really perspective compound class on this way of a hopeful AD drug development.

ACKNOWLEDGMENT

The authors gratefully acknowledge the support of their work by the Deutsche Forschungsgemeinschaft (DFG) within the project HI 687/8-1.
Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.

Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.

Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.

Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.

Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.

Tell and Hilgersoth AD-relevant protein kinase inhibitors

Munoz, L., Ranaivo, H. R., Sakai, M., McShane, R., Aerosa, S., and Martin, L., Latypova, X., Wilson, C., Marco, A. M., Karla, I. L., Victoria, C., Yardin, C., et al. (2013). Tau protein neurochemistry of Alzheimer's disease. Neurochem. Res. 38, 21–34. doi: 10.1186/1742-285X-38-21.
Tell and Hilgeroth

AD-relevant protein kinase inhibitors

Selciclib

Utreras, E., Maccioni, R., and Gonzalez-Billaut, C. (2009). Cyclin-dependent kinase 5 activator p35 overexpression and amyloid beta engram increase apoptosis in cultured neuronal cells. Neuroscience 161, 974–987. doi: 10.1016/j.neuroscience.2009.04.002

Verzeletti, K., Padov, R. A., Gleyzer, N., Mattos, V. M., and Scarpulla, R. C. (2006). PGC-1-related coactivator: immediate early expression and characterization of a CREB/NEF-1 binding domain associated with cytochrome c promoter occupancy and respiratory growth. Mol Cell Biol. 26, 7409–7419.

Voigt, B., Krug, M., Schächtele, C., Totzke, F., and Hilgeroth, A. (2008). Probing Novel 1-Aza-9-oxafluorenes as selective GSK-3β inhibitors. ChemMedChem 3, 120–126. doi: 10.1002/cmdc.200700175

Wen, Y., Planer, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., et al. (2008). Interspecies differences in cyclin-dependent kinase 3 and glycogen synthase kinase 3 beta mediated by neogenin signaling lead to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28, 2824–2832. doi: 10.1523/JNEUROSCI.4699-07.2008

Yang, E. J., Ahn, Y. S., and Chung, K. C. (2001). Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 276, 39819–39824. doi: 10.1074/jbc.M104091200

Zhu, X., Retikamp, C. A., Buxi, H., Takada, A., Perry, G., and Smith, M. A. (2000). Activation of p58 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer’s disease. J. Neurochem. Exp. Neurol. 59, 880–888. doi: 10.1046/j.1471-4159.2001.0046.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 05 July 2013; paper pending published: 19 August 2013; accepted: 04 October 2013; published online: 19 November 2013.

Copyright © 2013 Tell and Hilgeroth. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.